Christopher R. Cline

CIK: 0001943192

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)24 (72.7%)

Position reduction

Option Exercises (M)4 (12.1%)

Derivative conversions

Awards (A)5 (15.2%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TVTX

Travere Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (33 total)

TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
27.5K shares at avg. $62.00$1.7M
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Exercise(M)
Direct
20K shares at avg. $17.44$349K
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
400 shares at avg. $65.31$26K
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
1.9K shares at avg. $63.69$121K
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
20.7K shares at avg. $62.61$1.3M
TVTX
Travere Therapeutics, Inc.
Sep 2, 2026
Sale(S)
Direct
642 shares at avg. $66.37$43K
TVTX
Travere Therapeutics, Inc.
May 6, 2026
Sale(S)
Direct
310 shares at avg. $43.95$14K
TVTX
Travere Therapeutics, Inc.
May 5, 2026
Sale(S)
Direct
2.2K shares at avg. $46.65$102K
TVTX
Travere Therapeutics, Inc.
May 4, 2026
Exercise(M)
Direct
4.3K shares-
TVTX
Travere Therapeutics, Inc.
May 4, 2026
Award(A)
Performance-based restricted stock units
Direct
8.5K shares-
TVTX
Travere Therapeutics, Inc.
Apr 15, 2026
Sale(S)
Direct
1K shares at avg. $42.61$43K
TVTX
Travere Therapeutics, Inc.
Apr 14, 2026
Sale(S)
Direct
7.2K shares at avg. $41.93$304K
TVTX
Travere Therapeutics, Inc.
Apr 14, 2026
Sale(S)
Direct
9 shares at avg. $41.07$369.63
TVTX
Travere Therapeutics, Inc.
Apr 13, 2026
Award(A)
Direct
14K shares-
TVTX
Travere Therapeutics, Inc.
Apr 13, 2026
Sale(S)
Direct
65 shares at avg. $28.85$2K
TVTX
Travere Therapeutics, Inc.
Feb 4, 2026
Sale(S)
Direct
1.6K shares at avg. $32.14$53K
TVTX
Travere Therapeutics, Inc.
Feb 4, 2026
Sale(S)
Direct
110 shares at avg. $32.90$4K
TVTX
Travere Therapeutics, Inc.
Feb 3, 2026
Sale(S)
Direct
7.2K shares at avg. $32.12$233K
TVTX
Travere Therapeutics, Inc.
Jan 31, 2026
Award(A)
Direct
28.1K shares-
TVTX
Travere Therapeutics, Inc.
Dec 1, 2025
Exercise(M)
Direct
20K shares at avg. $16.23$325K
TVTX
Travere Therapeutics, Inc.
Dec 1, 2025
Sale(S)
Direct
20K shares at avg. $35.01$700K
TVTX
Travere Therapeutics, Inc.
Sep 4, 2025
Sale(S)
Direct
119 shares at avg. $19.71$2K
TVTX
Travere Therapeutics, Inc.
Sep 3, 2025
Sale(S)
Direct
454 shares at avg. $18.20$8K
TVTX
Travere Therapeutics, Inc.
Aug 27, 2025
Sale(S)
Direct
470 shares at avg. $17.31$8K
TVTX
Travere Therapeutics, Inc.
May 5, 2025
Sale(S)
Direct
1.8K shares at avg. $21.05$38K

		Type	Shares	Price		Ownership
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	27,473	$62.00	$1,703,241	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	20,000	$17.44	$348,800	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	400	$65.31	$26,124	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	1,900	$63.69	$121,004	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	20,735	$62.61	$1,298,175	Direct
Sep 2, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	642	$66.37	$42,610	Direct
May 6, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	310	$43.95	$13,625	Direct
May 5, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	2,181	$46.65	$101,744	Direct
May 4, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	4,250	-	$0	Direct
May 4, 2026	TVTX Travere Therapeutics, Inc.	Award(A) Performance-based restricted stock units	8,500	-	-	Direct
Apr 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	1,014	$42.61	$43,207	Direct
Apr 14, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	7,239	$41.93	$303,523	Direct
Apr 14, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	9	$41.07	$370	Direct
Apr 13, 2026	TVTX Travere Therapeutics, Inc.	Award(A)	14,000	-	$0	Direct
Apr 13, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	65	$28.85	$1,875	Direct
Feb 4, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	1,635	$32.14	$52,549	Direct
Feb 4, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	110	$32.90	$3,619	Direct
Feb 3, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	7,242	$32.12	$232,613	Direct
Jan 31, 2026	TVTX Travere Therapeutics, Inc.	Award(A)	28,130	-	$0	Direct
Dec 1, 2025	TVTX Travere Therapeutics, Inc.	Exercise(M)	20,000	$16.23	$324,600	Direct
Dec 1, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	20,000	$35.01	$700,202	Direct
Sep 4, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	119	$19.71	$2,345	Direct
Sep 3, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	454	$18.20	$8,263	Direct
Aug 27, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	470	$17.31	$8,136	Direct
May 5, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	1,784	$21.05	$37,553	Direct

1-25 of 33 transactions

About Cline Christopher R.

Cline Christopher R. (SEC CIK 0001943192) files insider reports with the SEC as CHIEF FINANCIAL OFFICER of Travere Therapeutics, Inc. (TVTX).

Signal8 holds 15 ownership filings by Cline Christopher R., all Form 4s, filed between Sep 5, 2024 and Sep 17, 2026. Those filings report 33 transactions, from Sep 4, 2024 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cline Christopher R.'s filings is in SAN DIEGO, CA.

Recent filings by Cline Christopher R.

Sep 15, 2026: Open-market sale of TVTX shares (Form 4, code S).
Sep 15, 2026: Option exercise of TVTX shares (Form 4, code M).
Sep 15, 2026: Open-market sales of TVTX shares (3 lines, Form 4, code S).
Sep 2, 2026: Open-market sale of TVTX shares (Form 4, code S).
May 6, 2026: Open-market sale of TVTX shares (Form 4, code S).

Other insiders filing for Travere Therapeutics, Inc. (TVTX)

Dube Eric M, CHIEF EXECUTIVE OFFICER
ROTE WILLIAM E., Chief Research Officer
Heerma Peter, EVP, CHIEF COMMERCIAL OFFICER
Inrig Jula, EVP, Head of R&D & CMO
REED ELIZABETH E, Chief Legal Officer and GC
Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER

How to read Form 4 transaction codes